{"id":"W4402565645","doi":"10.1016/j.annonc.2024.08.2285","title":"LBA44 Pembrolizumab vs ipilimumab in advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Ipilimumab; Oncology; Melanoma; Internal medicine; Phases of clinical research; Immunotherapy; Cancer research; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004114942,0.001230705,0.002238309,0.0003875099,0.0005496825,0.001776612,0.0008878841,0.001408778,0.002644365],"category_scores_gemma":[0.002116254,0.0005348035,0.003015044,0.0006293479,0.0007171425,0.001649487,0.0005807788,0.003830831,0.0009031847],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001205456,"about_ca_system_score_gemma":0.001046688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00151276,"about_ca_topic_score_gemma":0.002355472,"domain_scores_codex":[0.9987583,0.0005525661,0.00005521513,0.000201439,0.0001434375,0.0002889826],"domain_scores_gemma":[0.9982084,0.00038939,0.0005750165,0.000221079,0.0001176163,0.0004885817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8378795,0.01350401,0.02638134,0.0008952561,0.008832894,0.0001961899,0.0002338931,0.003120595,0.009513877,0.0002988313,0.005478906,0.09366477],"study_design_scores_gemma":[0.3635003,0.3655716,0.2389838,0.0002814166,0.01209211,0.0005520926,0.0003789237,0.003291818,0.00421773,0.0009864247,0.01000609,0.0001376912],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9857482,0.0080579,0.0004669073,0.0005961388,0.0002401581,0.0004120136,0.002133946,0.00004638589,0.00229828],"genre_scores_gemma":[0.9887543,0.003003462,0.0004143029,0.001086598,0.0002865052,0.0004368149,0.003213126,0.00003141264,0.002773422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004114942,"threshold_uncertainty_score":0.02176213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.047359941220065,"score_gpt":0.3919900992177938,"score_spread":0.3446301579977288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}